Q2 just closed.. positions are locked.. and corporate balance sheets are loaded!
Check your seatbelts, family.. this rocket is leaving the atmosphere!
Drop your top Q3 DAT picks below! 👇 To the moon! 🌕
Sitting at $0.82 right now.. absolute crazy, once-in-a-lifetime opportunity before the big Solana jump! Do not sleep on this entry level.. numbers do not lie!
Hey guys..
*updating this because it didn't even scratch the surface of how massive this tech actually is!*
MBOT’s LIBERTY system targets complex vascular procedures that are a massive pain for both doctors and patients. This isn't just a lab concept—it was tested by the absolute best research-doctors in top-tier world-class hospitals (including Memorial Sloan Kettering).
Look at these perfect metrics from the official ACCESS-PVI report.. absolutely flawless:
• 100% successful robotic navigation in all cases.. zero switching to manual manipulation!
• 0% adverse device effects reported.. a perfect safety profile!
• 92% relative reduction in radiation exposure for the operator!
• Maximum 5/5 performance score from investigators on ease of use, tool stability, and overall satisfaction!
But here is the real kicker that Wall Street doesn't know how to price yet: LIBERTY is the first miniaturized, portable, single-use endovascular robotic system on the market. It completely eliminates the millions in upfront costs and massive physical footprint required by old capital equipment.
Because it's a disposable, single-use device, it's a pure razor-and-blade recurring revenue model!
Every single procedure means a new sale!
Right now it’s approved for vascular/blood-clot adjacent procedures, but they are already successfully testing it for massive routine monitoring applications like Prostate cancer screenings.
The TAM expansion here is just ridiculous.
This company is introducing a brand new class of robots.. At ~$1.87 right now, the market is completely mispricing this asset. It's stupid cheap. A rare ground-floor entry point before the entire market wakes up and sends it to the moon..
Don't miss this ride!! 🚀🚀
Hey guys.. Just wanted to share some insane data from the latest ACCESS-PVI clinical trial for the LIBERTY system.. This is an absolute game-changer for the medical robotics space!
Look at these perfect metrics from the official report.. absolutely flawless:
* 100% successful robotic navigation in all cases.. zero switching to manual manipulation!
* 0% adverse device effects reported.. a perfect safety profile!
* 92% relative reduction in radiation exposure for the operator!
* Maximum 5/5 performance score from investigators on ease of use, tool stability, and overall satisfaction!
LIBERTY is the first miniaturized, portable, single-use endovascular robotic system on the market.. It completely eliminates the high costs and massive footprint required by old, complex capital equipment.
This company is introducing a brand new class of robots.. The current stock price is a total steal, a rare ground-floor entry point before the entire market wakes up and sends it to the moon.. Don't miss this ride!!
Hey guys.. Just wanted to share some insane data from the latest ACCESS-PVI clinical trial for the LIBERTY system.. This is an absolute game-changer for the medical robotics space!
Look at these perfect metrics from the official report.. absolutely flawless:
* 100% successful robotic navigation in all cases.. zero switching to manual manipulation!
* 0% adverse device effects reported.. a perfect safety profile!
* 92% relative reduction in radiation exposure for the operator!
* Maximum 5/5 performance score from investigators on ease of use, tool stability, and overall satisfaction!
LIBERTY is the first miniaturized, portable, single-use endovascular robotic system on the market.. It completely eliminates the high costs and massive footprint required by old, complex capital equipment.
This company is introducing a brand new class of robots.. The current stock price is a total steal, a rare ground-floor entry point before the entire market wakes up and sends it to the moon.. Don't miss this ride!! 🚀🚀
Hey guys.. Just wanted to share some insane data from the latest ACCESS-PVI clinical trial for the LIBERTY system.. This is an absolute game-changer for the medical robotics space!
Look at these perfect metrics from the official report.. absolutely flawless:
* 100% successful robotic navigation in all cases.. zero switching to manual manipulation!
* 0% adverse device effects reported.. a perfect safety profile!
* 92% relative reduction in radiation exposure for the operator!
* Maximum 5/5 performance score from investigators on ease of use, tool stability, and overall satisfaction!
LIBERTY is the first miniaturized, portable, single-use endovascular robotic system on the market.. It completely eliminates the high costs and massive footprint required by old, complex capital equipment.
This company is introducing a brand new class of robots.. The current stock price is a total steal, a rare ground-floor entry point before the entire market wakes up and sends it to the moon.. Don't miss this ride!! 🚀🚀
The inclusion goes live at US market open on June 29, 2026, right after the semi-annual Russell reconstitution.. Massive milestone for the stock, expect some serious volume and institutional eyes on this one!
So we all saw the White Diamond "research" report on Microbot Medical today.. The stock plummeted 15% and the weak hands are already running for the hills.. Let’s take a deep breath, look at the facts with cold, scientific eyes and understand how market mechanics actually work..
This is a textbook short-seller hit piece designed to bleed retail investors by triggering pure, unadulterated panic!
They are attacking the Liberty system because of its "disposable" model and high costs.. Does this sound familiar? It should, because the "experts" have been wrong about every major medical robotic breakthrough in history.. Let's look at the empirical evidence:
• Intuitive Surgical (ISRG): Back in 2013, shorts were screaming that the Da Vinci robot was a "expensive toy".. They claimed hospitals would never swallow the massive maintenance costs and that surgeons preferred manual work.. Fast forward to today: robotics are the global standard, the stock is up thousands of percentage points, and the shorts were absolutely crushed!
• Exact Sciences (EXAS): Remember when Citron Research claimed the company was worth $0? They called the science "flawed" and said insurance would never pay for it.. Today, Cologuard is a multi-billion dollar success that changed the industry.. The shorts didn't care about the science; they only cared about the panic!
The shorts at White Diamond are demonizing the single-use (disposable) model.. They are completely ignoring the reality of modern infection control and engineering precision.. The Liberty system solves the most critical, "life-or-death" issue in the field: Radiation exposure!
When a surgeon can perform a complex endovascular procedure from a remote console—without standing for 8 hours in a 20lb lead vest that destroys their back and exposes them to cancer-causing radiation—all these flimsy financial arguments about "cost per procedure" become irrelevant!
That is the true Game-Changer that they are intentionally trying to hide from you!
This 15% drop is a rare, gift-wrapped buying opportunity.. It’s an incredibly attractive entry price for anyone who understands that radical technology always faces resistance from those looking to make a quick buck off FUD (Fear, Uncertainty and Doubt)..
While they talk about "commercial failure" the engineering reality shows we are moving toward a future of autonomous, robotic surgery!
Bottom line: Buy the dip.. Don't let the shorts steal your shares at a discount while they're sweating! 🚀🩺
#MBOT #Biotech #Investing #Robotics #BuyTheDip #ShortSqueeze